{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Science Desk", "lead_paragraph": "Worried that millions of Americans are using prescription opiate painkillers to get high rather than to ease severe chronic pain, drug makers are working on ways to prevent abuse. Cooperating closely with government officials and pain specialists, the companies are educating doctors, rewriting warning labels and tracking pills as they move from pharmacy to patient.", "headline": {"main": "Drug Makers Hope to Kill The Kick In Pain Relief"}, "abstract": "Fifty million Americans suffer from chronic pain, which requires using prescription opiate painkillers; concerns over growing abuse of pain killing drugs has caused several drug companies to explore chemical ways to discourage misuse, including pills that contain neutralizing element that is released when pills are tampered with or taken in large quantities therefore leaving abuser without high; education of doctors and pharmacists as another step in abuse reduction discussed; photos (M)", "print_page": "1", "word_count": 1159, "_id": "4fd239138eb7c8105d7ccd50", "snippet": "Worried that millions of Americans are using prescription opiate painkillers to get high rather than to ease severe chronic pain, drug makers are working on ways to prevent abuse.    Cooperating closely with government officials and pain specialists,...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/04/20/science/drug-makers-hope-to-kill-the-kick-in-pain-relief.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "DRUGSTORES"}, {"name": "subject", "value": "OPIUM"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PAIN"}, {"name": "subject", "value": "DOCTORS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "DRUG ABUSE AND TRAFFIC"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Sandra", "lastname": "BLAKESLEE"}], "original": "By SANDRA BLAKESLEE"}, "document_type": "article", "pub_date": "2004-04-20T00:00:00Z", "section_name": "Science; Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Magazine Desk", "lead_paragraph": "I know what you're thinking. Hillary Clinton and health care? Been there. Didn't do that! No, it's not 1994; it's 2004. And believe it or not, we have more problems today than we had back then. Issues like soaring health costs and millions of uninsured have yet to fix themselves. And now we are confronting a new set of challenges associated with the arrival of the information age, the technological revolution and modern life.", "headline": {"main": "Now Can We Talk About Health Care?"}, "abstract": "Sen Hillary Rodham Clinton article on health care crisis she says has become more complicated since reform plan she worked on 10 years ago was rejected; warns new problems like genetic mapping, aging population and globalization are combining with old problems like skyrocketing costs and skyrocketing numbers of uninsured to overwhelm health care system; urges Americans across political spectrum to work together to change health care system before it collapses under new challenges; cites need to change flawed way we finance care; discusses problems and possible solutions; photo (L)", "print_page": "26", "word_count": 5599, "_id": "4fd29f5d8eb7c8105d882ac9", "snippet": "I know what you're thinking. Hillary Clinton and health care? Been there. Didn't do that!    No, it's not 1994; it's 2004. And believe it or not, we have more problems today than we had back then. Issues like soaring health costs and millions of...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/04/18/magazine/now-can-we-talk-about-health-care.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "GENETICS AND HEREDITY"}, {"name": "subject", "value": "FINANCES"}, {"name": "subject", "value": "AGED"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}], "byline": {"person": [{"firstname": "Hillary", "middlename": "Rodham", "lastname": "Clinton", "rank": 1, "role": "reported", "organization": ""}], "original": "By Hillary Rodham Clinton"}, "document_type": "article", "pub_date": "2004-04-18T00:00:00Z", "section_name": "Health; Magazine"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Representative Rick Renzi, a freshman Republican, voted for the new Medicare prescription drug benefit, billed by Republican leaders as a boon to the elderly. But Mr. Renzi has not found throngs of grateful constituents expressing gratitude. On the contrary, Mr. Renzi said, after a town hall meeting here, ''I hear lots of honest concern about the unknown, and there's fear in the unknown.'' For example, he said, voters want to know if the drug benefit is truly voluntary, or if they will have to drop coverage they already have to get it.", "headline": {"main": "In Arizona, Unease Over New Medicare Drug Law"}, "abstract": "Republican Arizona Rep Rick Renzi finds confusion and skepticism among constituents about new Medicare prescription drug benefit; was initially opposed to plan, but backed it in end; says now it was good first step, but he favors allowing imports of low-cost prescription drugs from abroad; those knowledgeable about new law believe it may help low-income people, but doubt they will benefit personally; many others simply do not understand complex provisions of law; photos (M)", "print_page": "14", "word_count": 1356, "_id": "4fd239b78eb7c8105d7cd613", "snippet": "Representative Rick Renzi, a freshman Republican, voted for the new Medicare prescription drug benefit, billed by Republican leaders as a boon to the elderly. But Mr. Renzi has not found throngs of grateful constituents expressing gratitude.    On...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/04/18/us/in-arizona-unease-over-new-medicare-drug-law.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "RENZI, RICK"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "glocations", "value": "ARIZONA"}, {"name": "subject", "value": "INTERNATIONAL TRADE AND WORLD MARKET"}, {"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "AGED"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "LAW AND LEGISLATION"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Robert", "lastname": "PEAR"}], "original": "By ROBERT PEAR"}, "document_type": "article", "pub_date": "2004-04-18T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Top Food and Drug Administration officials admitted yesterday that they barred the agency's top expert from testifying at a public hearing about his conclusion that antidepressants cause children to become suicidal because they viewed his findings as alarmist and premature. ''It would have been entirely inappropriate to present as an F.D.A. conclusion an analysis of data that were not ripe,'' Dr. Robert Temple, the Food and Drug Administration's associate director of medical policy, said in an interview. ''This is a very serious matter. If you get it wrong and over-discourage the use of these medicines, people could die.''", "headline": {"main": "Expert Kept From Speaking At Antidepressant Hearing"}, "abstract": "Food and Drug Administration officials admit that they barred Dr Andrew D Mosholder, agency's top expert, from testifying at public hearing about his conclusion that antidepressants cause children to become suicidal because they viewed his findings as alarmist and premature; FDA associate director Dr Robert Temple seeks to quell growing controversy into whether agency's warnings on Mar 22 about antidepressant therapy were sufficient; internal agency documents show that federal health officials are divided on issue; controversy started when Mosholder was reviewing data on GlaxoSmithKline's drug Paxil and saw disturbing number of problems listed under category 'emotional liability' (M)", "print_page": "16", "word_count": 769, "_id": "4fd24f4d8eb7c8105d7f1f2a", "snippet": "Top Food and Drug Administration officials admitted yesterday that they barred the agency's top expert from testifying at a public hearing about his conclusion that antidepressants cause children to become suicidal because they viewed his findings as...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/04/16/us/expert-kept-from-speaking-at-antidepressant-hearing.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "TEMPLE, ROBERT"}, {"name": "persons", "value": "MOSHOLDER, ANDREW D"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "GLAXOSMITHKLINE"}, {"name": "subject", "value": "CHILDREN AND YOUTH"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "ANTIDEPRESSANTS"}, {"name": "subject", "value": "PAXIL (DRUG)"}, {"name": "subject", "value": "DEPRESSION (MENTAL)"}, {"name": "subject", "value": "SUICIDES AND SUICIDE ATTEMPTS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Gardiner", "lastname": "HARRIS"}], "original": "By GARDINER HARRIS"}, "document_type": "article", "pub_date": "2004-04-16T00:00:00Z", "section_name": "Health; U.S."}], "meta": {"hits": 4, "offset": 0, "time": 50}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}